LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 61

Search options

  1. Article ; Online: ChatGPT: immutable insertion in health research and researchers' lives.

    Vieira, Aléxia Gabriela da Silva / Saconato, Humberto / Eid, Raquel Afonso Caserta / Nawa, Ricardo Kenji

    Einstein (Sao Paulo, Brazil)

    2024  Volume 22, Issue spe1, Page(s) eCE0752

    Language English
    Publishing date 2024-03-11
    Publishing country Brazil
    Document type Letter
    ZDB-ID 2418293-X
    ISSN 2317-6385 ; 2317-6385
    ISSN (online) 2317-6385
    ISSN 2317-6385
    DOI 10.31744/einstein_journal/2024CE0752
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis.

    Pinto, Ana Carolina Pereira Nunes / Piva, Sara R / Rocha, Aline / Gomes-Neto, Mansueto / Atallah, Álvaro N / Saconato, Humberto / Trevisani, Virginia Fm

    The Cochrane database of systematic reviews

    2023  Volume 6, Page(s) CD014605

    Abstract: Background: Although exercise is recommended as part of the cystic fibrosis (CF) therapeutic routine, adherence to exercise is still limited. Digital health technologies can provide easy-to-access health information and may help improve healthcare and ... ...

    Abstract Background: Although exercise is recommended as part of the cystic fibrosis (CF) therapeutic routine, adherence to exercise is still limited. Digital health technologies can provide easy-to-access health information and may help improve healthcare and outcomes in individuals with long-term conditions. However, its effects for delivering and monitoring exercise programs in CF have not yet been synthesized.
    Objectives: To evaluate the benefits and harms of digital health technologies for delivering and monitoring exercise programs, increasing adherence to exercise regimens, and improving key clinical outcomes in people with CF.
    Search methods: We used standard, extensive Cochrane search methods. The latest search date was 21 November 2022.
    Selection criteria: We included randomized controlled trials (RCTs) or quasi-RCTs of digital health technologies for delivering or monitoring exercise programs in CF.
    Data collection and analysis: We used standard Cochrane methods. Our primary outcomes were 1. physical activity, 2. self-management behavior, and 3. pulmonary exacerbations. Our secondary outcomes were 4. usability of technologies, 5. quality of life, 6. lung function, 7. muscle strength, 8. exercise capacity, 9. physiologic parameters, and 10.
    Adverse events: We used GRADE to assess certainty of evidence.
    Main results: We identified four parallel RCTs (three single-center and one multicenter with 231 participants aged six years or older). The RCTs evaluated different modes of digital health technologies with distinct purposes, combined with diverse interventions. We identified important methodologic concerns in the RCTs, including insufficient information on the randomization process, blinding of outcome assessors, balance of non-protocol interventions across groups, and whether the analyses performed corrected for bias due to missing outcome data. Non-reporting of results may also be a concern, especially because some planned outcome results were reported incompletely. Furthermore, each trial had a small number of participants, resulting in imprecise effects. These limitations on the risk of bias, and on the precision of effect estimates resulted in overall low- to very low-certainty evidence. We undertook four comparisons and present the findings for our primary outcomes below. There is no information on the effectiveness of other modes of digital health technologies for monitoring physical activity or delivering exercise programs in people with CF, on adverse events related to the use of digital health technologies either for delivering or monitoring exercise programs in CF, and on their long-term effects (more than one year). Digital health technologies for monitoring physical activity Wearable fitness tracker plus personalized exercise prescription compared to personalized exercise prescription alone One trial (40 adults with CF) evaluated this outcome, but did not report data for any of our primary outcomes. Wearable fitness tracker plus text message for personalized feedback and goal setting compared to wearable fitness tracker alone The evidence is very uncertain about the effects of a wearable fitness tracker plus text message for personalized feedback and goal setting, compared to wearable technology alone on physical activity measured by step count at six-month follow-up (mean difference [MD] 675.00 steps, 95% confidence interval [CI] -2406.37 to 3756.37; 1 trial, 32 participants). The same study measured pulmonary exacerbation rates and reported finding no difference between groups. Web-based application to record, monitor, and set goals on physical activity plus usual care compared to usual care alone Using a web-based application to record, monitor, and set goals on physical activity plus usual care may result in little to no difference on time spent in moderate-to-vigorous physical activity measured via accelerometry compared to usual care alone at six-month follow-up (MD -4 minutes/day, 95% CI -37 to 29; 1 trial, 63 participants). Low certainty-evidence from the same trial suggests that the intervention may result in little to no difference on pulmonary exacerbations during 12 months of follow-up (median 1 respiratory hospitalization, interquartile range [IQR] 0 to 3) versus control (median 1 respiratory hospitalization, IQR 0 to 2; P = 0.6). Digital health technologies for delivering exercise programs Web-based versus face-to-face exercise delivery The evidence is very uncertain about the effects of web-based compared to face-to-face exercise delivery on adherence to physical activity as assessed by the number of participants who completed all exercise sessions after three months of intervention (risk ratio 0.92, 95% CI 0.69 to 1.23; 1 trial, 51 participants).
    Authors' conclusions: The evidence is very uncertain about the effects of an exercise program plus the use of a wearable fitness tracker integrated with a social media platform compared with exercise prescription alone and on the effects of receiving a wearable fitness tracker plus text message for personalized feedback and goal setting, compared to a wearable fitness tracker alone. Low-certainty evidence suggests that using a web-based application to record, monitor, and set goals on physical activity plus usual care may result in little to no difference in time spent in moderate-to-vigorous physical activity, total time spent in activity, pulmonary exacerbations, quality of life, lung function, and exercise capacity compared to usual care alone. Regarding the use of digital health technologies for delivering exercise programs in CF, the evidence is very uncertain about the effects of using a wearable fitness tracker plus personalized exercise prescription compared to personalized exercise prescription alone. Further high-quality RCTs, with blinded outcome assessors, reporting the effects of digital health technologies on clinically important outcome measures, such as physical activity participation and intensity, self-management behavior, and the occurrence of pulmonary exacerbations in the long term are needed. The results of six ongoing RCTs identified through our searches may help clarify the effects of different modes of digital health technologies for delivering and monitoring exercise programs in people with CF.
    MeSH term(s) Adult ; Humans ; Cystic Fibrosis/therapy ; Digital Technology ; Exercise ; Exercise Therapy ; Multicenter Studies as Topic ; Muscle Strength ; Quality of Life
    Language English
    Publishing date 2023-06-09
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ISSN 1469-493X
    ISSN (online) 1469-493X
    DOI 10.1002/14651858.CD014605.pub2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis.

    Lírio, Juliana / Giraldo, Paulo César / Sarmento, Ayane Cristine / Costa, Ana Paula Ferreira / Cobucci, Ricardo Ney / Saconato, Humberto / Eleutério Júnior, José / Gonçalves, Ana Katherine

    Revista da Associacao Medica Brasileira (1992)

    2022  Volume 68, Issue 2, Page(s) 261–267

    MeSH term(s) Administration, Oral ; Antifungal Agents/therapeutic use ; Candidiasis, Vulvovaginal/drug therapy ; Candidiasis, Vulvovaginal/microbiology ; Female ; Humans ; Recurrence ; Vagina
    Chemical Substances Antifungal Agents
    Language English
    Publishing date 2022-02-28
    Publishing country Brazil
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 731969-1
    ISSN 1806-9282 ; 0104-4230 ; 0004-5241 ; 0102-843X
    ISSN (online) 1806-9282
    ISSN 0104-4230 ; 0004-5241 ; 0102-843X
    DOI 10.1590/1806-9282.20210916
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The relationship between the authentic leadership of nurses and structural empowerment: a systematic review.

    Valle, Rebeca Beatriz Lucena Ribeiro do / Balsanelli, Alexandre Pazetto / Taminato, Mônica / Saconato, Humberto / Gasparino, Renata

    Revista da Escola de Enfermagem da U S P

    2021  Volume 55, Page(s) e03667

    Abstract: Objective: To verify the relationship between authentic leadership of nurses and structural empowerment.: Method: This is a systematic review carried out at the Virtual Health Library on the Journal Portal of the Coordination for the Improvement of ... ...

    Abstract Objective: To verify the relationship between authentic leadership of nurses and structural empowerment.
    Method: This is a systematic review carried out at the Virtual Health Library on the Journal Portal of the Coordination for the Improvement of Higher Education Personnel, Online System for the Search and Analysis of Medical Literature, Scientific Electronic Library Online and Science Direct/Embase, and consulted until April 2019. Studies with nurses, evidencing the relationship between authentic leadership and structural empowerment, published between 2012 and 2018 in Brazilian Portuguese, English or Spanish were included.
    Results: Five studies were included, with variables other than structural empowerment: job satisfaction, burnout, bulling, mental health, performance, social capital, working environment, nurse retention, and quality of care. Authentic leadership showed a positive relationship with structural empowerment, improving engagement and job satisfaction, reducing burnout and increasing quality of care.
    Conclusion: Health institutions, in addition to Canada, where researchers on this topic are located, can invest in authentic leadership to improve structural empowerment by providing greater commitment from nurses, increased job satisfaction and quality of care provided.
    MeSH term(s) Burnout, Professional ; Humans ; Job Satisfaction ; Leadership ; Nurses ; Power, Psychological
    Language Portuguese
    Publishing date 2021-04-16
    Publishing country Brazil
    Document type Journal Article ; Systematic Review
    ZDB-ID 2411320-7
    ISSN 1980-220X ; 1980-220X
    ISSN (online) 1980-220X
    ISSN 1980-220X
    DOI 10.1590/S1980-220X2019029003667
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Sodium-glucose cotransporter-2 inhibitors for type 2 diabetes mellitus in adults: An overview of 46 systematic reviews.

    Augusto, Gustavo A / Cassola, Nicolle / Dualib, Patrícia M / Saconato, Humberto / Melnik, Tamara

    Diabetes, obesity & metabolism

    2021  Volume 23, Issue 10, Page(s) 2289–2302

    Abstract: Aims: To summarize the evidence from systematic reviews (SRs) of randomized controlled trials (RCTs) evaluating the efficacy and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors versus placebo or active comparators for type 2 diabetes ... ...

    Abstract Aims: To summarize the evidence from systematic reviews (SRs) of randomized controlled trials (RCTs) evaluating the efficacy and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors versus placebo or active comparators for type 2 diabetes mellitus.
    Materials and methods: We searched six databases between 2014 and 2021. We assessed the quality of evidence using Assessment of Multiple Systematic Reviews (AMSTAR 2) and Grading of Recommendations Assessment, Development and Evaluation (GRADE) and summarized the main outcome results according to their evidence of benefit (PROSPERO ID: CRD42019132431).
    Results: We included 46 SRs, comprising 175 RCTs and 136 096 participants. The results showed "clear evidence of benefit" in relation to: myocardial infarction (odds ratio [OR]/hazard ratio [HR] 0.85 to 0.91); cardiovascular mortality (OR/HR 0.67 to 0.86); heart failure (OR/HR 0.64 to 0.69); albuminuria progression and composite renal outcome (relative risk [RR]/HR 0.55 to 0.63); glycated haemoglobin (HbA1c) versus placebo (mean difference [MD] -0.49% to -0.77% [5.4 to 8.4 mmol/mol]); and weight versus placebo (MD -1.09 kg to -2.99 kg). "Possible benefit" was observed in relation to major adverse cardiovascular events (OR/HR 0.80 to 0.89), all-cause mortality and nonalcoholic fatty liver disease. SGLT2 inhibitors showed "clear evidence of no effect or equivalence" in relation to stroke and fractures. "Clear evidence of harm" was observed in relation to genital infections (RR/OR 2.06 to 5.25) and ketoacidosis (HR/OR 1.36 to 2.20). Regarding amputation risk and urinary tract infections, we found "no conclusions possible due to lack of evidence".
    Conclusions: Our results showed that SGLT2 inhibitors have beneficial effects in relation to renal and cardiovascular outcomes (except for stroke), HbA1c and weight. Further studies are needed to assess urinary infections and amputation risk.
    MeSH term(s) Adult ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology ; Glucose ; Humans ; Hypoglycemic Agents/therapeutic use ; Sodium ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Systematic Reviews as Topic
    Chemical Substances Hypoglycemic Agents ; Sodium-Glucose Transporter 2 Inhibitors ; Sodium (9NEZ333N27) ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2021-07-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.14470
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Economic burden of respiratory syncytial and parainfluenza viruses in children of upper-middle-income countries: a systematic review.

    Rocha-Filho, César Ramos / Ramalho, Gabriel Sodré / Martins, Johnny Wallef Leite / Lucchetta, Rosa Camila / Pinto, Ana Carolina Pereira Nunes / da Rocha, Aline Pereira / Trevisani, Giulia Fernandes Moça / Reis, Felipe Sebastião de Assis / Ferla, Laura Jantsch / Mastroianni, Patrícia de Carvalho / Correa, Luci / Saconato, Humberto / Trevisani, Virgínia Fernandes Moça

    Jornal de pediatria

    2023  Volume 99, Issue 6, Page(s) 537–545

    Abstract: Objective: To identify and assess the current evidence available about the costs of managing hospitalized pediatric patients diagnosed with Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in upper-middle-income countries.: ... ...

    Abstract Objective: To identify and assess the current evidence available about the costs of managing hospitalized pediatric patients diagnosed with Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in upper-middle-income countries.
    Methods: The authors conducted a systematic review across seven key databases from database inception to July 2022. Costs extracted were converted into 2022 International Dollars using the Purchasing Power Parity-adjusted. PROSPERO identifier: CRD42020225757.
    Results: No eligible study for PIV3 was recovered. For RSV, cost analysis and COI studies were performed for populations in Colombia, China, Malaysia, and Mexico. Comparing the total economic impact, the lowest cost per patient at the pediatric ward was observed in Malaysia ($ 347.60), while the highest was in Colombia ($ 709.66). On the other hand, at pediatric ICU, the lowest cost was observed in China ($ 1068.26), while the highest was in Mexico ($ 3815.56). Although there is no consensus on the major cost driver, all included studies described that the medications (treatment) consumed over 30% of the total cost. A high rate of inappropriate prescription drugs was observed.
    Conclusion: The present study highlighted how RSV infection represents a substantial economic burden to health care systems and to society. The findings of the included studies suggest a possible association between baseline risk status and expenditures. Moreover, it was observed that an important amount of the cost is destinated to treatments that have no evidence or support in most clinical practice guidelines.
    MeSH term(s) Humans ; Child ; Infant ; Developing Countries ; Financial Stress ; Respiratory Syncytial Virus Infections ; Respiratory Syncytial Virus, Human ; Parainfluenza Virus 3, Human ; Hospitalization
    Language English
    Publishing date 2023-05-26
    Publishing country Brazil
    Document type Systematic Review ; Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 731324-x
    ISSN 1678-4782 ; 0021-7557
    ISSN (online) 1678-4782
    ISSN 0021-7557
    DOI 10.1016/j.jped.2023.05.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis

    Juliana Lírio / Paulo César Giraldo / Ayane Cristine Sarmento / Ana Paula Ferreira Costa / Ricardo Ney Cobucci / Humberto Saconato / José Eleutério Júnior / Ana Katherine Gonçalves

    Revista da Associação Médica Brasileira, Vol 68, Iss 2, Pp 261-

    a systematic review and meta-analysis

    2022  Volume 267

    Keywords Medicine (General) ; R5-920
    Language English
    Publishing date 2022-02-01T00:00:00Z
    Publisher Associação Médica Brasileira
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Online: Indications for accurate and appropriate use of personal protective equipment for healthcare professionals. A systematic review.

    Peccin, Maria Stella / Duarte, Márcio Luís / Imoto, Aline Mizusaki / Taminato, Mônica / Saconato, Humberto / Puga, Maria Eduarda / Franco, Eduardo Signorini Bicas / Camargo, Erika Barbosa / Gottems, Leila Bernarda Donato / Atallah, Álvaro Nagib

    Sao Paulo medical journal = Revista paulista de medicina

    2022  Volume 140, Issue 1, Page(s) 56–70

    Abstract: Background: The speed of the spread of coronavirus disease 2019 (COVID-19) has put enormous pressure on hospitals and other healthcare facilities. This, together with blockages in several countries, has hindered the availability and accessibility of the ...

    Abstract Background: The speed of the spread of coronavirus disease 2019 (COVID-19) has put enormous pressure on hospitals and other healthcare facilities. This, together with blockages in several countries, has hindered the availability and accessibility of the necessary personal protective equipment (PPE).
    Objective: To identify, systematically evaluate and summarize the available scientific evidence on the efficacy, safety, safe use and reuse of PPE for healthcare professionals, for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
    Design and setting: Systematic review of studies analyzing products for disinfecting and enabling reuse of PPE for coronavirus within the evidence-based health program of a federal university in São Paulo (SP), Brazil.
    Methods: A systematic search of the relevant literature was conducted in the PubMed, EMBASE, Cochrane Library, CINAHL, SCOPUS, Web of Science and LILACS databases, for articles published up to November 30, 2020.
    Results: Ten studies were selected. These analyzed the use of N95, surgical and cotton masks, face shields, flexible enclosures with plastic covers or polycarbonate intubation boxes and plastic curtains; and also PPE disinfection using several substances.
    Conclusion: Combined use of a face shield with a N95 mask proved to be superior to other associations for protecting healthcare workers. Some products are useful for disinfecting PPE, such as 70% ethanol, 0.1% sodium hypochlorite and a mixture of quaternary ammonium and H2O2, and hydrogen peroxide. Ultraviolet light and dry heat at 70 °C can be used to decontaminate N95 masks.
    Registration number: DOI: 10.17605/OSF.IO/4V5FD at the OPENSCIENCE Framework.
    MeSH term(s) Brazil ; COVID-19 ; Delivery of Health Care ; Health Personnel ; Humans ; Hydrogen Peroxide ; Personal Protective Equipment ; SARS-CoV-2
    Chemical Substances Hydrogen Peroxide (BBX060AN9V)
    Language English
    Publishing date 2022-01-25
    Publishing country Brazil
    Document type Journal Article ; Systematic Review
    ZDB-ID 1203171-9
    ISSN 1806-9460 ; 1516-3180 ; 0035-0362
    ISSN (online) 1806-9460
    ISSN 1516-3180 ; 0035-0362
    DOI 10.1590/1516-3180.2021.0128.R1.18052021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial.

    Tomazini, Bruno Martins / Tramujas, Lucas / Medrado, Fernando Azevedo / Gomes, Samara Pinheiro do Carmo / Negrelli, Karina Leal / Murinize, Gabriela Souza / Santos, Renato Hideo Nakagawa / Vianna, Bruna Martins Pereira / Piotto, Bruna Fornazieri / Veiga, Thabata Silva / Santos, Bianca Rodrigues do / Peneluppi Horak, Ana Clara / Lemos, Olivia Mora Cavalcante / Lopes, Marcela de Almeida / Olicheski, Beatriz Baptista / Campones, Diego Lurentt / Peixoto, Luiz Angelo Alencar / Basilio, Aline Dos Anjos Chaves / Gebara, Otavio Celso Eluf /
    Lopes, Ana Tarina Alvarez / Saconato, Humberto / Valeis, Nanci / Miranda, Tamiris Abait / Laranjeira, Ligia Nasi / Santucci, Eliana Vieira / Carlin, Aaron Foster / Esko, Jeffrey David / Gordts, Phillip Leo Stephan Marie / Tsimikas, Sotirios / Cavalcanti, Alexandre Biasi

    PloS one

    2024  Volume 19, Issue 2, Page(s) e0299197

    Abstract: Background: Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent in vitro activity against SARS-CoV-2 virus. The safety and efficacy of halofuginone in Covid-19 patients has not been studied.: Methods: We conducted a ... ...

    Abstract Background: Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent in vitro activity against SARS-CoV-2 virus. The safety and efficacy of halofuginone in Covid-19 patients has not been studied.
    Methods: We conducted a phase II, randomized, double-blind, placebo-controlled, dose ranging, safety and tolerability trial of halofuginone in symptomatic (≤ 7 days), mostly vaccinated, non-hospitalized adults with mild to moderate Covid-19. Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. The primary outcome was the decay rate of the SARS-CoV-2 viral load logarithmic curve within 10 days after randomization.
    Results: From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log10 within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). There was no difference on bleeding episodes or serious adverse events at 28 days.
    Conclusions: Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.
    MeSH term(s) Adult ; Humans ; COVID-19 ; SARS-CoV-2 ; Time Factors ; Double-Blind Method ; Piperidines ; Quinazolinones
    Chemical Substances halofuginone (L31MM1385E) ; Piperidines ; Quinazolinones
    Language English
    Publishing date 2024-02-23
    Publishing country United States
    Document type Randomized Controlled Trial ; Multicenter Study ; Clinical Trial, Phase II ; Journal Article
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0299197
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Hospitalization costs of coronaviruses diseases in upper-middle-income countries: A systematic review.

    Rocha-Filho, César Ramos / Martins, Johnny Wallef Leite / Lucchetta, Rosa Camila / Ramalho, Gabriel Sodré / Trevisani, Giulia Fernandes Moça / da Rocha, Aline Pereira / Pinto, Ana Carolina Pereira Nunes / Reis, Felipe Sebastião de Assis / Ferla, Laura Jantsch / Mastroianni, Patrícia de Carvalho / Correa, Luci / Saconato, Humberto / Trevisani, Virgínia Fernandes Moça

    PloS one

    2022  Volume 17, Issue 3, Page(s) e0265003

    Abstract: Background: COVID-19, SARS and MERS are diseases that present an important health burden worldwide. This situation demands resource allocation to the healthcare system, affecting especially middle- and low-income countries. Thus, identifying the main ... ...

    Abstract Background: COVID-19, SARS and MERS are diseases that present an important health burden worldwide. This situation demands resource allocation to the healthcare system, affecting especially middle- and low-income countries. Thus, identifying the main cost drivers is relevant to optimize patient care and resource allocation.
    Objective: To systematically identify and summarize the current status of knowledge on direct medical hospitalization costs of SARS, MERS, or COVID-19 in Upper-Middle-Income Countries.
    Methods: We conducted a systematic review across seven key databases (PubMed, EMBASE, BVS Portal, CINAHL, CRD library, MedRxiv and Research Square) from database inception to February 2021. Costs extracted were converted into 2021 International Dollars using the Purchasing Power Parity-adjusted. The assessment of quality was based on the protocol by the BMJ and CHEERS. PROSPERO 2020: CRD42020225757.
    Results: No eligible study about SARS or MERS was recovered. For COVID-19, five studies presented cost analysis performed in Brazil, China, Iran, and Turkey. Regarding total direct medical costs, the lowest cost per patient at ward was observed in Turkey ($900.08), while the highest in Brazil ($5,093.38). At ICU, the lowest was in Turkey ($2,984.78), while the highest was in China ($52,432.87). Service care was the most expressive (58% to 88%) cost driver of COVID-19 patients at ward. At ICU, there was no consensus between service care (54% to 87%) and treatment (72% to 81%) as key burdens of total cost.
    Conclusion: Our findings elucidate the importance of COVID-19 on health-economic outcomes. The marked heterogeneity among studies leaded to substantially different results and made challenging the comparison of data to estimate pooled results for single countries or regions. Further studies concerning cost estimates from standardized analysis may provide clearer data for a more substantial analysis. This may help care providers and policy makers to organize care for patients in the most efficient way.
    MeSH term(s) COVID-19/economics ; COVID-19/epidemiology ; Costs and Cost Analysis ; Delivery of Health Care/economics ; Hospitalization/economics ; Humans ; SARS-CoV-2
    Language English
    Publishing date 2022-03-11
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Systematic Review
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0265003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top